ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2006 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2006--ImmunoGen, Inc. (Nasdaq: IMGN - News), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three- and nine-month periods ended March 31, 2006 - the third quarter and first nine months of the Company's 2006 fiscal year.